Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Multiple Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Naurex
- 22 May 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
- 24 Feb 2015 New trial record